Immunotheraphy of Metastatic Prostate Cancer Using Dendritic Cells Pulsed with Normal Prostate Tissue Antigens
Abstract
The focus of this grant is to develop a vaccination strategy for patients with metastatic prostate cancer using DC- based vaccines loaded with normal prostate tissue-derived antigens. The key advantage of using normal prostate antigens, as opposed to using tumor-specific antigens, is that it will provide a universal and unlimited source of antigens for vaccination, and in combination with dendritic cells offers a powerful vaccination strategy that will be readily available to all patients with prostate cancer. Having established a TRAMP colony, protocols for measuring diseases progression in the TRAMP mice and protocols for measuring TRAMP C-i tumor growth in mice we encountered two setbacks: 1) The TRAMP colony was severely decimated due to viral infection and 2) Generation of dendritic cells was severely compromised due to lack of access to a critical reagent. in response to these setbacks we have (1) regenerated the TRAMP colony-to be completed in March-April and (2) have developed a new, highly reliable method of generating high quality murine DC and demonstrated their functionality. We are currently testing the proposed vaccination protocols with normal prostate antigens in the TRAMP C-i tumor model and will commence the parallel studies in the autochthonous TRAMP model when mice become available. Despite these setbacks, the experimental goals of the project will be met.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1999
- Accession Number
- ADA385269
Entities
People
- Eli Gilboa
Organizations
- Duke University